Boston Scientific deployed the LUX-Dx II+ Insertable Cardiac Monitor, which uses an enhanced dual-stage algorithm to automatically detect and verify potential arrhythmias in patients before sending alerts to clinicians. The device is implanted under the skin for long-term continuous heart monitoring.

The LUX-Dx II+ ICM system uses a two-stage detection process: the first stage identifies candidate arrhythmia events from continuous subcutaneous ECG signals, and the second stage uses adaptive morphology analysis, noise discrimination, and pattern detectors to verify events and reject false positives, reducing false positives by 53% compared to earlier approaches. The system received FDA clearance and CE Mark in 2023. It is the only insertable cardiac monitor with independently programmable atrial tachycardia and atrial fibrillation algorithms, and supports remote programming via a paired smartphone app (myLUX).